Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 988

1.

Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.

Rumi E, Cazzola M.

Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14713. [Epub ahead of print] Review.

PMID:
28444727
2.

The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.

Das L, Gitlin M, Siegartel LR, Makenbaeva D.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):133-140. doi: 10.1080/14737167.2017.1305892. Epub 2017 Mar 22. Review.

PMID:
28287008
3.

Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature.

Ramachandran KC, Narayanan G, Nair SG, Thambi SM, Kamala LH, Gopinath P, Sreedharan H.

Cytogenet Genome Res. 2016;150(3-4):273-280. doi: 10.1159/000458164. Epub 2017 Mar 3. Review.

PMID:
28253493
4.

Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.

How J, Zhou A, Oh ST.

Ther Adv Hematol. 2017 Mar;8(3):107-118. doi: 10.1177/2040620716680333. Epub 2016 Dec 8. Review.

5.

Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.

Toro-Tobón D, Agosto S, Ahmadi S, Koops M, Bruder JM.

Am J Case Rep. 2017 Feb 27;18:203-207. Review.

6.

PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.

Andrei M, Bandarchuk A, Abdelmalek C, Kundra A, Gotlieb V, Wang JC.

Am J Case Rep. 2017 Feb 17;18:173-180. Review.

7.

GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm.

Imoto N, Harunori N, Furukawa K, Tange N, Murase A, Hayakawa M, Ichihara M, Iwata Y, Kosugi H.

Intern Med. 2017;56(4):435-439. doi: 10.2169/internalmedicine.56.6920. Epub 2017 Feb 15. Review.

8.

GATA factor mutations in hematologic disease.

Crispino JD, Horwitz MS.

Blood. 2017 Apr 13;129(15):2103-2110. doi: 10.1182/blood-2016-09-687889. Epub 2017 Feb 8. Review.

PMID:
28179280
9.

Myeloproliferative neoplasm stem cells.

Mead AJ, Mullally A.

Blood. 2017 Mar 23;129(12):1607-1616. doi: 10.1182/blood-2016-10-696005. Epub 2017 Feb 3. Review.

PMID:
28159736
10.

The role of the extracellular matrix in primary myelofibrosis.

Leiva O, Ng SK, Chitalia S, Balduini A, Matsuura S, Ravid K.

Blood Cancer J. 2017 Feb 3;7(2):e525. doi: 10.1038/bcj.2017.6. Review.

11.

Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.

Vrontaki E, Melagraki G, Voskou S, Phylactides MS, Mavromoustakos T, Kleanthous M, Afantitis A.

Mini Rev Med Chem. 2017;17(3):188-204. Review.

PMID:
28143387
12.

Polycythemia Vera Management and Challenges in the Community Health Setting.

Gerds AT, Dao KH.

Oncology. 2017;92(4):179-189. doi: 10.1159/000454953. Epub 2017 Jan 18. Review.

13.

Age-associated changes in human hematopoietic stem cells.

Pang WW, Schrier SL, Weissman IL.

Semin Hematol. 2017 Jan;54(1):39-42. doi: 10.1053/j.seminhematol.2016.10.004. Epub 2016 Oct 20. Review.

PMID:
28088986
14.

Hematological disorders and pulmonary hypertension.

Mathew R, Huang J, Wu JM, Fallon JT, Gewitz MH.

World J Cardiol. 2016 Dec 26;8(12):703-718. doi: 10.4330/wjc.v8.i12.703. Review.

15.

Splenic irradiation for splenomegaly: A systematic review.

Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE.

Cancer Treat Rev. 2017 Feb;53:47-52. doi: 10.1016/j.ctrv.2016.11.016. Epub 2016 Dec 22. Review.

PMID:
28063304
16.

Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.

Choi DC, Tremblay D, Iancu-Rubin C, Mascarenhas J.

Ann Hematol. 2017 Jun;96(6):919-927. doi: 10.1007/s00277-016-2915-4. Epub 2017 Jan 6. Review.

PMID:
28062906
17.

Acquired von Willebrand Syndrome.

Mital A.

Adv Clin Exp Med. 2016 Nov-Dec;25(6):1337-1344. doi: 10.17219/acem/64942. Review.

18.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R.

Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Review.

PMID:
28028029
19.

Emerging treatments for classical myeloproliferative neoplasms.

Vannucchi AM, Harrison CN.

Blood. 2017 Feb 9;129(6):693-703. doi: 10.1182/blood-2016-10-695965. Epub 2016 Dec 27. Review.

PMID:
28028027
20.

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Rumi E, Cazzola M.

Blood. 2017 Feb 9;129(6):680-692. doi: 10.1182/blood-2016-10-695957. Epub 2016 Dec 27. Review.

Supplemental Content

Loading ...
Support Center